<h4>Aims</h4>Glucagon-like peptide-1 receptor (GLP-1R) agonists improve glycemic control and promote weight loss in diabetes and obesity but are also associated with gastrointestinal adverse events, including nausea and emesis in many patients. This evidence concerns the gene GLP1R and diabetes mellitus.